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Introduction
Several reports suggest that the administration of in vitro
expanded stem cells might promote liver regeneration [1, 2].
Sources of pluripotent cells with hepatic potential include adipose
tissue [3], bone marrow derived-stem cells [4–6] and embryonic
stem cells [7]. However, the mechanisms involved in hepatic
regeneration are not completely understood and the relative con-
tribution of mature hepatocytes and of resident stem cells is still
intensely debated [8]. It has been suggested that bone marrow
derived stem cells may engraft in the liver undergoing transdiffer-
entiation or fusion [9–11]. However, more recent studies have
suggested that tissue regeneration triggered by exogenous stem
cells may depend on the release of paracrine factors rather than on
stem cell transdifferentiation [12–15]. The liver is known to have
the capacity to regenerate after injury induced by chemicals, partial
surgical resection or sepsis [8, 16]. Following partial hepatectomy,
most of the quiescent hepatocytes in the remnant liver tissue
quickly proliferate leading to rapid restoration of liver mass [17].
Whether resident stem cells are involved in such regeneration
remains unknown. We recently described in the adult human liver
a population of pluripotent resident liver stem cells (HLSC) able to
localize within the injured liver and contribute to liver regeneration
Human liver stem cell-derived microvesicles accelerate hepatic
regeneration in hepatectomized rats
M. B. Herrera 
a, e, #, V. Fonsato 
a, #, S. Gatti 
b, #, M. C. Deregibus 
a, A. Sordi 
b, 
D. Cantarella 
c, R. Calogero 
c, B. Bussolati 
a, C. Tetta 
e, d, G. Camussi 
a, *
a Department of Internal Medicine, Research Center for Experimental Medicine (CeRMS), and 
Center for Molecular Biotechnology, Torino, Italy
b Center for Surgical Research, Fondazione IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, Milano, Italy
c Department of Clinical and Biological Sciences, University of Torino, Torino, Italy
d Fresenius Medical Care, Bad Homburg, Germany
e Sister Spa, Palazzo Pignano, Italy
Received: April 17, 2009; Accepted: July 10, 2009
Abstract
Several studies indicate that adult stem cells may improve the recovery from acute tissue injury. It has been suggested that they may
contribute to tissue regeneration by the release of paracrine factors promoting proliferation of tissue resident cells. However, the fac-
tors involved remain unknown. In the present study we found that microvesicles (MVs) derived from human liver stem cells (HLSC)
induced in vitro proliferation and apoptosis resistance of human and rat hepatocytes. These effects required internalization of MVs in
the hepatocytes by an  4-integrin-dependent mechanism. However, MVs pre-treated with RNase, even if internalized, were unable to
induce hepatocyte proliferation and apoptosis resistance, suggesting an RNA-dependent effect. Microarray analysis and quantitative 
RT-PCR demonstrated that MVs were shuttling a specific subset of cellular mRNA, such as mRNA associated in the control of transcrip-
tion, translation, proliferation and apoptosis. When administered in vivo, MVs accelerated the morphological and functional recovery of
liver in a model of 70% hepatectomy in rats. This effect was associated with increase in hepatocyte proliferation and was abolished by
RNase pre-treatment of MVs. Using human AGO2, as a reporter gene present in MVs, we found the expression of human AGO2 mRNA
and protein in the liver of hepatectomized rats treated with MVs. These data suggested a translation of the MV shuttled mRNA into hepa-
tocytes of treated rats. In conclusion, these results suggest that MVs derived from HLSC may activate a proliferative program in rem-
nant hepatocytes after hepatectomy by a horizontal transfer of specific mRNA subsets.
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when injected in mice with acute liver failure induced by ace-
toaminophene [18]. Recently, it has been proposed that a dynamic
stem cell regulation may occur as result of differentiated cell-stem
cell interaction via a microvesicle (MV)-based genetic information
transfer [19]. Progenitor/stem cells may re-direct the behaviour of
differentiated cells by a horizontal transfer of mRNA shuttled by
MVs [20, 21] and conversely differentiated cells may influence the
stem cell phenotype [19]. MVs are derived from the endosomal
membrane compartment after fusion with the plasma membrane
and are shed from the cell surface of activated cells. MVs are now
recognized to have an important role in cell to cell communication
[22]. Ratajczak and coworkers [20] demonstrated that MVs derived
from embryonic stem cells may contribute to the cell-fate decision
and may represent one of the critical components that support self-
renewal and expansion of stem cells. We demonstrated that MVs
derived from endothelial progenitor cells may activate an angio-
genic program in mature quiescent endothelial cells [21] and that
mRNA shuttled by MVs derived from mesenchymal stem cells may
induce repair of acute kidney injury [23]. Recently Kostin and
Popescu [24] demonstrated that the interstitial Cajal-like cells that
have been described to be present in the heart [25], communicate
with neighbouring cells via shedding of MVs.
In the present study we characterized the MVs derived from
HLSC and their potential to induce proliferation and apoptosis
resistance in cultured human hepatocytes and to favour liver
regeneration in the model of 70% hepatectomy in rats.
Materials and methods
Isolation and characterization of HLSC
HLSC were isolated from human cryopreserved normal adult hepatocytes
(Lonza, Basel, Switzerland). The isolation, culture and characterization of
HLSC were performed as previously described [18]. By cytofluorimetric
analysis HLSC expressed the mesenchymal stem cell markers CD29,
CD44, CD73, CD90 but not the haematopoietic and endothelial markers
CD34, -CD45, -CD14, -CD117, -CD133, -CD31, -CD144. Moreover, HLSC
were positive for  5-integrin,  4-integrin,  6-integrin and - v 3-integrin.
By immunofluorescence HLSC were positive for the hepatic markers
human albumin and  -fetoprotein, for the resident stem cells markers
vimentin and nestin and were negative for the oval cell markers CD34,
CD117 and cytocheratin19 [18]. In addition, HLSC expressed the embry-
onic stem cell markers nanog, Oct4, SOX2 and SSEA4. Before use HLSC
were shown to undergo osteogenic, endothelial and hepatic differentiation
under appropriate culture conditions [18].
Isolation of MVs
MVs were obtained from supernatants of HLSC cultured overnight in 
 -MEM deprived of foetal calf serum (FCS). The viability of HLSC at the time
of MV collection was  99% as detected by trypan blue exclusion. After cen-
trifugation at 2000  gfor 20 min. cell-free supernatants were ultracentrifuged
at 100,000   g (Beckman Coulter Optima L-90K, Optima L-90K, Beckman
Coulter, Fullerton, CA, USA) for 1 hr at 4 C, washed in serum-free medium
199 containing Hepes 25 mM (Sigma, St. Louis, MO, USA) and   submitted
to a second ultracentrifugation in the same conditions [21, 23]. The protein
content of MV preparation was quantified by Bradford method (Bio-Rad,
Hercules, CA, USA). To trace MVs by fluorescent microscopy or cytofluo-
rimetry, MVs were labelled with the red fluorescent aliphatic chromophore
PKH26 (Sigma) [23]. Endotoxin contamination of MVs was excluded by
Limulus test (Charles River Laboratories, Inc., Wilmington, MA, USA).
In selected experiments MVs from HLSC were treated with 1 U/ml
RNase (Ambion, Inc., Austin, TX, USA) [21, 23] for 1 hr at 37 C, the reac-
tion was stopped by addition of 10 U/ml RNase inhibitor (Ambion) followed
by ultracentrifugation. The effectiveness of RNase treatment was evaluated
as previously described [23] by spectrophotometer analysis of total
extracted RNA (untreated: 4.1   0.3  g RNA/mg protein MVs; RNase
treated:  0.2  g RNA/mg protein MVs). As control, MVs were treated with
1 U/ml DNase (Ambion) for 1 hr at 37 C.
Cytofluorimetric analysis of MVs
The size of MVs was determined by cytofluorimetry as previously
described [21, 23] using beads of different sizes (1, 2 and 4  m; Molecular
Probes, Leiden, The Netherlands). The analysis was performed using a log
scale for forward scatter and side scatter parameters. Moreover, the size of
MVs, was evaluated by the Zetasizer Nano (Malvern Instruments, Malvern
Worcestershire, UK). Cytofluorimetric analysis for the detection of surface
molecules was performed as previously described [21, 23], using the
  following FITC- or PE-conjugated antibodies directed to: CD44
(Dakocytomation, Copenhagen, Denmark), CD29,  4-integrin, (BD
Pharmingen),  5-integrin,  6-integrin (BioLegend, San Diego, CA, USA)
and HLA-I (BD Pharmingen). FITC or PE mouse nonimmune isotypic IgG
(Dakocytomation, Copenhagen, Denmark) were used as control.
Culture of hepatocytes
Human hepatocytes (Lonza) were cultured in William’s medium supple-
mented with 10% of FCS, 7.5  g/ml hydrocortisone, 200  g/ml strepto-
mycin and 200 U/ml penicillin. Rat hepatocytes were obtained from liver of
healthy male Sprague–Dawley rats using a two-step collagenase perfusion
procedure and were cultured as previously described [26]. Cell viability
was greater than 90% as determined by trypan blue exclusion.
Incorporation of MVs in hepatocytes
To study the incorporation of MVs into hepatocytes, we incubated 
50  g/ml of MVs labelled with PKH-26 dye for 3 hrs at 37 C. We studied
the MV incorporation by cytofluorimetry and confocal microscopy (LSM 5
Pascal Confocal Microscope, Carl Zeiss International, Oberkochen, Germany).
To investigate the role of adhesion molecules expressed by MVs in
the incorporation in hepatocytes, MVs were pre-incubated (15 min. at
4 C) with blocking antibodies (1  g/ml) against the identified adhesion
molecules anti- 4-integrin (Biolegend),  6-integrin (Biolegend), CD29
( 1- integrin) (BD Pharmingen) or with soluble hyaluronic acid (sHA)
(100  g/ml from Rooster comb; Sigma) before the incubation with the
cells. In selected experiments labelled MVs were treated with 0.5 mM
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trypsin for 30 min. at 37 C and the integrity of MVs and removal of sur-
face molecules was checked by cytofluorimetric analysis.
Cell proliferation and apoptosis
Hepatocyte were seeded at 50,000 cells/well into 48-well plates in
William’s medium E (Gibco, Paisley, UK) deprived of FCS. DNA synthesis
was detected as incorporation of 5-bromo-2 -deoxy-uridine (BrdU) into the
cellular DNA after 48 hrs of culture. This time point was chosen on the base
of preliminary comparative experiments with [3H] thymidine incorporation.
Cells were then fixed with 0.5 M ethanol/HCl and incubated with nuclease
to digest the DNA. BrdU incorporated into the DNA was detected using an
anti-BrdU peroxidise conjugated antibody (Roche Applied Science,
Mannheim, Germany). Optical density was measured with an ELISA reader
at 405 nm.
Apoptosis was evaluated by terminal deoxynucleotidyl transferase-
mediated dUTP nick-end labelling (TUNEL) technology (Chemicon, CA,
USA) as previously described [27]. To induce apoptosis hepatocytes were
incubated with 5 mM of D-galactosamine (GalN) for 24 hrs in DMEM sup-
plemented with 2% FCS [28]. Apoptosis was also evaluated in paraffin-
embedded liver sections by TUNEL.
Gene array analysis
RNA extraction, samples labelling and 
hybridization on BeadChips
RNA was extracted from MVs using TRIZOL reagent (Invitrogen, Paisley,
UK) following the procedure suggested by the manufacturer. Total RNA was
quantified spectrophotometrically (Nanodrop ND-1000, Wilmington DE,
USA). cRNA was synthesized using three different quantities of total RNA
(0.25, 0.5 and 1 g). cRNA synthesis and labelling was done using Illumina
RNA Amplification Kit (Ambion) following the procedure suggested by man-
ufacturer. Sentrix
® Human-6 Expression BeadChip hybridization, washing
and staining were also done as suggested by the manufacturer. Arrays were
scanned on Illumina BeadStation 500 (Illumina, San Diego, CA, USA).
Microarray data analysis
BeadChip array data quality control was performed with Illumina
BeadStudio software version 3.0. Transcript average intensity signals were
calculated with BeadStudio without background correction. Raw data were
analysed using Bioconductor [29]. Average transcript intensities were log2
transformed and normalized by loess method [30].
A simple statistical linear model [21] was used to identify transcript
signals linearly correlated to the increment of total RNA concentration used
to prepare cRNA. In equation (1) yij is the observed expression level 
for transcript i in sample j (j   1, …, 6).   is the average expression level
of transcript i and  RNA represents the effect of total RNA concentration on
the expression level of transcript i.   represents random error for transcript
i and sample j, and it is assumed to be independent for each transcript and
sample, and normally distributed with mean 0 and variance  
2.
yij       RNA   ij
Transcripts characterized by a model with P   0.05, r
2   0.8, and a pos-
itive slope were selected (120; see additional information 1).
Transcripts annotation and data mining were performed with IPA 7.0
software (www.ingenuity.com). Microarray data were deposited on GEO
database (http://www.ncbi.nlm.nih.gov/projects/geo/) as geo accession
GSE15569.
Quantitative real time polymerase chain reaction
(Q-PCR)
Q-PCR was performed as previously described [31] on four different MV
preparations and on livers of Sprague–Dawley rats treated with MVs. Cell
cDNA was used to evaluate primers efficiency. The primers for the human
genes used for real time PCR were: (AGO2; forward 5  CTAGACCC-
GACTTTGGGACCT-3 , reverse 5 -GGGCACTTCTCTGGCTTGATA-3;
CHECK2; forward 5 -AGAAAGCTCTGGACCTTGTCAAGA-3 , reverse 5 -
TGGATTCATTTTCCTCAGACAGAA-3 ; CDK2; forward 5 -AATCCGCCTGGA-
CACTGAGA -3 , reverse 5 -TCCAGCAGCTTGACAATATTAGGA-3 ,  MATK
forward 5 -CCGCGACGTCATCCACTAC-3 , reverse 5 -TGTAATGCTCCAC-
CATGTCCAT-3  and the primers for the rat CCNA1 gene were: forward
primer 5 -AAGTCCTGGCATTCGATCTGA-3 , reverse primer 5 -TGCAACAT-
ACTTGGCCAAATT-3 . First-strand cDNA was produced from 200 ng of
mRNA using High Capacity cDNA Reverse Transcription Kit (Applied
Biosystems, Foster City, CA, USA). 20  l of RT-PCR mix, containing 1 
SYBR GREEN PCR Master Mix (Applied Biosystems), 200 nM of each
primer and, respectively, 1  l of MV cDNA, were assembled using a 48-
wells StepOneTM Real Time System (Applied Biosystems). Negative cDNA
controls (no cDNA) were cycled in parallel with each run.
RT-PCR
Total RNA extracted from livers of rats was submitted to RT-PCR using the
following primer for human AGO2 forward 5  CTAGACCCGACTTTGGGACCT-
3  and reverse 5 -GGGCACTTCTCTGGCTTGATA-3. Bands of the expected
size (90 pb) were detected in a 4% agarose gel after electrophoresis. cDNA
from a preparation of HLSC was used as positive control.
Immunoprecipitation and Western blot
Rat liver tissue was homogenized (TissueRuptor, Qiagen, Valencia, CA, USA).
Proteins were lysated with 1  l of lysis buffer containing 25 mM Tris￿HCl pH
7.6, 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS, 1 mM
PMSF, protease and phosphatase inhibitor cocktails (all from Sigma) as pre-
viously described [27]. The lysates after pre-clearing with protein A–coupled
Sepharose (Amersham, Buckinghamshire, UK) were incubated with human
anti-AGO2 antibody (Abcam, Cambridge, MA, USA) overnight at 4 C, under
agitation. Samples were subjected to SDS-PAGE in 8% acrylamide gel and
transferred to a nitrocellulose membrane as described [27]. Membrane was
revealed with a chemiluminescence reagent and analysed with Chemidoc
(Biorad, Hercules, CA, USA). Western blot was also performed on MV lysates
for detection of Staufen 2 using 8–16% linear gradient acrylamide gels
(Biorad) and anti-STAU2 mouse monoclonal antibody (Abcam).
Rat model of 70% hepatectomy
All experiments were performed in accordance with the Principles of
Laboratory Animal Care and approved by the Local Committee for
Experimental Animal Research. Adult Sprague–Dawley rats (Charles River,
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Calco, Italy) weighing 180–200 g were anesthetized and subjected to 70%
hepatectomy as previously described [17]. In sham-operated animals, livers
were briefly exposed outside the peritoneal cavity. Immediately after hepate-
ctomy, animals received an intravenous injection of 30  g HLSC-derived
MVs either untreated or RNase treated. Control rats received an equal vol-
ume of saline i.p. To measure hepatocyte proliferation in excised livers, rats
received an i.p. injection of BrdU (100 mg/kg) 2 hrs before being killed as
suggested by Lanier et al. [32] for the evaluation of hepatocellular prolifera-
tion in rodents. Rats were killed at 8, 24, 48 or 72 hrs after surgery to collect
the remnant liver. Blood was also withdrawn from the abdominal aorta and
serum was obtained by centrifugation (3000 rpm, 20 min.) to measure ala-
nine transaminase (ALT), aspartate transaminase (AST) and albumin. Six
animals were used for each time point. Liver samples were snap frozen in liq-
uid nitrogen and stored at  80 C until used in molecular biology studies.
Additional liver samples were paraffin embedded for histology, immunohis-
tochemistry and immunofluorescence analysis. Body and liver weights were
recorded at each post-operative time to assess liver regeneration rate that
was expressed as the ratio wet liver weight to body weight (%) [33].
Fig. 1 Cytofluorimetric characterization of HLSC-derived MVs and their incorporation into hepatocytes. (A) Representative FACS analyses of MVs show-
ing the size (with 1-, 2- and 4- m beads used as internal size standards) and the expression of  4-integrin,  5-integrin,  6-integrin, CD29, CD44 and
HLA-class I (dark lines) surface molecules. Dot lines indicate the isotypic controls. Ten different MV preparations were analysed with similar results. In
the  4-integrin, CD29, CD44 experiments the Kolmogrov–Smirnov statistical analyses between relevant antibodies and the isotypic control was signif-
icant (P   0.001). No significant expression of  5-integrin,  6-integrin and HLA class I was observed. (B) Western blot analysis of two different MV
preparations showing the expression of Staufen 2 (Stau 2) ribonucleoprotein. (C) Representative confocal microscopy micrographs of internalization
by human hepatocytes (3 hrs at 37 C) of MVs labelled with red fluorescent PKH26. Where indicated MVs were pre-incubated trypsin (0.5 mM; Try-MV),
with 1  g/ml blocking monoclonal antibodies against CD29,  4- and  6-integrin or with 100  g/ml of sHA to block CD44. Three experiments were per-
formed with similar results. Original magnification:  630. (D) Representative FACS analyses of internalization by hepatocytes of MVs labelled with
PKH26 (black areas) pre-incubated with trypsin (0.5 mM; Try-MV) or with 1  g/ml blocking monoclonal antibodies against CD29,  4- and  6-integrin
or sHA. Black areas indicate the internalization of untreated MVs. In the first panel white area indicates the negative control (cells incubated with vehi-
cle alone). In the other panels white areas indicate internalization of MVs after incubation trypsin or with blocking antibodies or sHA. Three experiments
were performed with similar results.J. Cell. Mol. Med. Vol 14, No 6B, 2010
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Functional category mRNA Description
Transcription regulators CASP8AP2 CASP8 associated protein 2
DMRT2 Doublesex and mab-3 related transcription factor 2
HOXC12 Homeobox C12
NFIX Nuclear factor I/X (CCAAT-binding transcription factor)
HOXA3 Homeobox C3
MIB2 Mindbomb homolog 2
NFIX Nuclear factor I/X
NR2E3 Nuclear receptor subfamily 2
SIM2 Single-minded homolog 2
Translation regulator EIF2C2 (AGO2) Eukaryotic translation initiation factor 2C, 2
Enzymes/metabolism CREG2 Cellular repressor of E1A-stimulated genes 2
FKBP9 FK506 binding protein 9, 63 kD
IMPDH1 IMP (inosine monophosphate) dehydrogenase 1
MRE11A MRE11 meiotic recombination 11 homolog A (S. cerevisiae)
ST3GAL4 ST3  -galactoside  -2,3-sialyltransferase 4
STK40 Serine/threonine kinase 40
ACPP Acid phosphatase, prostate
PGC Progastricsin (pepsinogen C)
B3GAT1  -1,3-glucuronyl-transferase 1
CDK2 Cyclin-dependent kinase 2
CHEK2 Cell cycle checkpoint regulator
LTK Leucocyte receptor tyrosine kinase
MATK Megakaryocyte-associated tyrosine kinase
PTEN Phosphatase and tensin homolog
PTPN2 Protein tyrosine phosphatase
Transporter AP3M2 Adaptor-related protein complex 3, mu 2 subunit
ATP1A2 ATPase, Na
 /K
  transporting,  2
  polypeptide
PODXL ATP binding
SLC22A16 Organic cation/carnitine transporter
Ion channel CACNG1 Calcium channel, voltage-dependent,   subunit 1
G-protein coupled receptor MC3R Melanocortin 3 receptor
Other TMEM179 Transmembrane protein 179
TOR1AIP2 Torsin A interacting protein 2
TSPAN7 Tetraspanin 7
VASP Vasodilator-stimulated phosphoprotein
Table 1 MV-shuttled mRNA involved in transcription, translation and cell proliferation1610 © 2009 The Authors
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Morphological studies
For hepatic histology, 5- m-thick paraffin liver sections were routinely
stained with haematoxylin and eosin. Immunohistochemistry for detection of
hepatocyte proliferation was performed as previously described [34] using
anti-BrdU (Dakocytomation) or anti-PCNA (Santa Cruz Biotechnology, Santa
Cruz CA, USA) monoclonal antibodies. Ten non-consecutive sections were
counted for BrdU
  and PCNA
  hepatocytes at 200  magnification. Confocal
microscopy analysis was performed on frozen sections for detection of spe-
cific human AGO2 protein. Sections were blocked and labelled with rabbit
anti-human AGO2 (Abcam) (1:300 dilution). Omission of the primary anti-
bodies or substitution with non-immune rabbit IgG was used as controls.
Alexa Fluor 488 anti-rabbit (Molecular Probes) was used as secondary anti-
body. Hoechst 33258 dye (Sigma) was added for nuclear staining.
Oil red O staining for hepatic triglyceride 
detection
Frozen liver sections were assayed by a modification of the Folch method
for triglyceride content using Oil red O staining [34]. Frozen sections of
liver were fixed for 10 min. in neutral buffered 10% formalin and stained
with Oil red O (Sigma) for 10 min., counterstained with haematoxylin for 
2 min., and cover slipped with a water-based mounting medium.
Biochemical analyses
Serum ALT and AST levels were measured using a standard clinical auto-
matic analyser. Serum rat albumin was determined by ELISA (Alpco diag-
nostic, Salem, NH, USA).
Statistical analysis
Data were analysed using the t-tests, ANOVA with Newmann–Keuls’ or ANOVA
with Dunnet’s multicomparison tests as appropriate. A P-value of  0.05
was considered significant.
Results
Characterization of HLSC-derived MVs
By cytofluorimetric analyses MVs produced by HLSC were detected
mainly below the forward scatter signal corresponding to 1- m
beads (Fig. 1A). When determined by Zetasizer, the size of MVs
Fig. 2 Proliferative and anti-apoptotic effects of HLSC-derived MVs on human hepatocytes. (A) 10  M BrdU was added to 50,000 cells/well into 48-well
plates incubated for 48 hrs in William’s E medium deprived of FCS in the presence of vehicle alone (Ctrl; white bar) or of MVs (5  g/ml grey bar; 
30  g/ml dark bar) or of RNase-treated MVs (shaded bar). Results are expressed as mean   S.D. of three different experiments performed in tripli-
cate. Analyses of variance with Newmann–Keuls multicomparison test was performed; *P   0.05 MV versus vehicle alone (Ctrl); §P   0.05 MV treated
with RNase versus MV untreated. (B) The percentage of apoptotic cells was evaluated by the TUNEL assay. We used, as apoptotic stimulus, HLSC incu-
bated with 5 mM GalN for 24 hrs in DMEM supplemented with 2% FCS. Controls (white bars) included hepatocytes incubated with vehicle alone (Ctrl)
and hepatocytes incubated with vehicle containing RNase submitted to the same procedure of inactivation as in samples of RNase-treated MVs as
described in ‘Material and methods’ (RNase alone); hepatocytes incubated with 5, 15, 30  g/ml MVs (black bars); hepatocytes incubated with RNase-
treated MVs (grey bar). Results are expressed as mean   S.D. of three different experiments performed in duplicate. Analyses of variance with
Newmann–Keuls multicomparison test was performed; *P   0.05 MV versus vehicle alone; §P   0.05 MV RNase treated versus MV untreated.J. Cell. Mol. Med. Vol 14, No 6B, 2010
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ranged from 80 nm to 1  m, with a mean value of 195 nm.
Cytofluorimetric analyses showed the presence of several adhesion
molecules also present on HLSC plasma membrane such as  4-
integrin, CD29 and CD44. MVs did not express  5- and  6-integrins
and HLA-class I (Fig. 1A) at variance with the cells of origin [18].
Gene array analyses of HLSC-derived MVs
mRNA extracted from MVs was submitted to microarray analy-
sis to define which transcripts were present [21]. A total of 65
transcripts were found with this procedure; 60 were associated
to Entrez gene identifiers [30] by IPA 6.0 analysis (see additional
information). This observation indicated that MVs shuttled a
specific subset rather than a random sample of cellular mRNA.
MVs contained mRNA related to several cell functions involved
in the control of transcription and metabolism (Table 1). In par-
ticular the following genes, that were detected in MVs, are
known to be involved in cell proliferation: MATK, MRE11A,
CHECK2, MYH11, VASP and CDK2. In particular, CDK2 gene has
been shown to be involved in liver regeneration [35]. Moreover,
MVs contained the AGO2 (EIF2C2) gene which is a translation
Fig. 3 Effect of MVs on biochemical parameters and on remnant liver/body weight ratio into 70% herpatectomized rats. (A) Aspartate aminotransferase,
(B) alanine aminotransferase were measured in serum in sham operated rats (Ctrl; white bars), in 70% hepatectomized rats (black bars) and in 70%
hepatectomized rats treated with 30  g/ml MVs (grey bars) and expressed as U/L. Data are expressed as mean   S.D. relative quantity of six different
rats per group. Analyses of variance with Newmann–Keuls multicomparison test was performed; *P   0.05 MV versus Ctrl; §P   0.05 MV treated rats
versus MV untreated. (C) Albumin was measured in serum of sham operated rats (Ctrl; white bar), in 70% hepatectomized rats (black bars) and in 70%
hepatectomized rats treated with 30  g/ml MVs (grey bars) and expressed as mg/ml. Data are expressed as mean   S.D. relative quantity of six dif-
ferent rats per group. Analyses of variance with Newmann–Keuls multicomparison test was performed; *P   0.05 MV treated rats versus MV untreated;
#P   0.05 all experimental groups versus Ctrl. (D) Remnant liver/body weight ratio was evaluated into 70% hepatectomized rats MV untreated (black
bars) or MV treated (gray bars). Data are expressed as mean 6 S.D. relative quantity of six different rats per group. T student test *P   0.05 treated
rats versus MV untreated.regulator with a critical role in the control of microRNA produc-
tion [36]. Quantitative real time PCR confirmed the presence in
MVs of genes randomly chosen from those detected by
Microarray (AGO2, CHEK2, CDK2, MATK).
Moreover, MVs were shown to contain Staufen 2 (Fig. 1B) a ribonu-
cleoprotein involved in the transport and stability of mRNA [37].
Incorporation of MVs in cultured hepatocytes
MVs labelled with PKH26 dye were incorporated by cultured
human hepatocytes after 3 hrs of incubation at 37 C as shown by
FACS analysis and confocal microscopy (Fig. 1A, C). In order to
investigate the role of adhesion molecules expressed by the MV
surface in the incorporation in target cells, MVs were pre-incu-
bated (15 min., at 4 C) with blocking antibodies against the iden-
tified adhesion molecules or with sHA to block CD44 (Fig. 1C, D).
MV treatment with anti- 4-integrin blocking antibody inhibited MV
incorporation in human hepatocytes. Blockade of CD44 or CD29
only slightly reduced incorporation of MVs (Fig. 1D). The anti- 6-
integrin blocking antibody used as negative control did not prevent
MV internalization. Moreover, removal of surface molecules by
trypsin treatment of MVs inhibited their incorporation in human
hepatocytes confirming the relevance of surface expressed mole-
cules in the process of MV internalization by target cells. Similar
results were obtained using rat hepatocytes (data not shown).
In vitro proliferative and anti-apoptotic effects 
of MVs
Incubation of human hepatocytes with MVs derived from HLSC
promoted a significant proliferation in respect to control cells incu-
bated with vehicle alone (Fig. 2A). In addition, incubation of human
hepatocytes with increasing doses of MVs significantly inhibited
apoptosis induced by GalN (Fig. 2B). However, when MVs were
incubated with RNase, that we previously showed to induce a com-
plete degradation of the RNA shuttled by MVs without affecting
their structure [23], proliferation and apoptosis resistance elicited
by MVs were significantly reduced (Fig. 2A, B). As previously
shown [23], RNase treatment did not modify the expression of sur-
face molecules or the internalization of MVs (not shown). These
results suggest that the MV biological effects were mediated by the
transfer of mRNA following MV internalization, as previously
described [21, 23]. DNase treatment was ineffective (not shown).
HLSC-derived MVs enhanced hepatic 
regeneration in rat with 70% hepatectomy
In the rat model of 70% hepatectomy, we observed a significant
rise in AST and ALT and a significant reduction in serum albumin
at 24, 48 and 72 hrs (Fig. 3A–C). In MV-treated rats the rise of AST
1612 © 2009 The Authors
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Fig. 4 Effects of MVs on histological
changes into 70% hepatectomized rats.
Representative light microscopy micro-
graphs of liver histology at 24, 48 and 
72 hrs after 70% hepatectomy (70% Hpt) in
rats injected or not with 30  g of MVs. (A)
Haematoxylin & Eosin staining; (B) Oil red
O staining for triglycerides. Original magni-
fication:  200.J. Cell. Mol. Med. Vol 14, No 6B, 2010
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and ALT was significantly lower after 72 hrs (Fig. 3A, B) in respect
to the untreated. Moreover, in MV-treated rats an enhanced pro-
duction of albumin was detected at 24 hrs (Fig. 3C). The liver/body
weight ratio gradually increased after 70% hepatectomy in rats
treated or not with MVs. However, after 72 hrs a significant
enhancement of liver/body ratio was observed in MV-treated in
respect to untreated rats (Fig. 3D). The histological examination of
70% hepatectomized rats showed a marked hepatocyte swelling
and vacuolization (Fig. 4A). The staining for triglyceride with Oil
red O indicated a diffuse hepatic steatosis (Fig. 4B). When animals
were treated with MVs, the lesions were less severe at all the time
points in respect to animals with 70% hepatectomy treated with
vehicle alone (Fig. 4A) and the steatosis was minimal or absent
(Fig. 4B). As shown in Figs 5 and 6, MV-treatment of rats with
70% hepatectomy significantly enhanced in vivo hepatocyte pro-
liferation as detected by BrdU
  and PCNA
  cells in respect to hepa-
tectomized rats injected with vehicle alone (Figs 5A, B and 6A, B).
The enhanced proliferation was detected at all the different time
points after MV treatment. RNase treatment of MVs abrogated
MV-induced recovery of liver lesions and significantly inhibited
hepatic proliferation induced by MVs (Figs 5A and 6A). The activa-
tion of a proliferative program in hepatocytes was also confirmed
by Q-PCR showing a significantly enhanced expression of cyclin
A1 in rats treated with MVs in respect to the untreated (Fig. 6C).
After hepatectomy a significant enhancement of apoptosis of
hepatocytes was seen only after 72 hrs (Fig. 7A, B). When hepa-
tectomized rats were treated with MVs, a significant reduction of
apoptosis was observed.
In vivo evidence of de novo human protein
expression in the liver of hepatectomized rats
treated with human MVs
Q-PCR and RT-PCR for human AGO2, used as reporter gene, con-
firmed the accumulation of injected MVs within the liver of hepa-
tectomized rats treated with MVs but not in those treated with
vehicle alone (Fig. 8A, B). Using anti-human AGO2 antibody, the
protein was detected both by Western blot analysis (Fig. 8C) of
liver extracts and by immunofluorescence (Fig. 8D) in hepatec-
tomized rats treated with MVs but not in those treated with vehi-
cle alone. By confocal microscopy AGO2 protein was detected
with a perinuclear localization in liver parenchyma. HLSC-derived
MVs contained AGO2 mRNA (Table 1) but not the protein (not
shown). These observations suggest that human specific mRNA
shuttled by MVs could be translated in protein in liver cells during
regeneration.
Discussion
In the present study, we demonstrated that MVs derived from
human HLSC promoted hepatocyte proliferation and suppressed
hepatocyte cell death. MV administration accelerated in vivo liver
regeneration in 70% hepatectomized rats. The RNase treatment of
MVs abrogated both the in vitro and in vivo effects of MVs, sug-
gesting that the RNA shuttled by MVs was the final effector of their
biological effect.
The 70% hepatectomy in rats is a classical model to study liver
regeneration. The remaining hepatic lobes of the rats can restore
Fig. 5 Effect of MVs on liver cell proliferation evaluated as BrdU incorpo-
ration in 70% hepatectomized rats. (A) Quantification of BrdU
  cells/high
power field (hpf). BrdU was injected intraperitoneally 2 hrs before rats
being killed. Hepatectomized rats injected with vehicle   white bars;
hepatectomized rats injected with 30  g MVs   black bars; hepatec-
tomized rats injected with 30  g RNase-treated MVs   shaded bars.
Data are expressed as mean   S.D. relative quantity of six different rats
per group. Analyses of variance with Newmann–Keuls multicomparison
test was performed; *P   0.05 MV treated versus MV untreated rats; 
§P   0.05 rats injected with RNase-treated MVs versus rats injected with
MVs. (B) Representative micrographs of BrdU uptake performed on sec-
tions of livers 24, 48 and 72 hrs after 70% hepatectomy in rats treated
with vehicle (70% Hpt) or treated with 30  g MVs (70% Hpt   MV).
Original magnification:  200.1614 © 2009 The Authors
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the liver mass two weeks after partial hepatectomy [17]. It has
been suggested that the regeneration process is due to the prolif-
eration of residual mature hepatocytes that re-enter into the cell
cycle and undergo proliferation [8]. It is not clear whether resident
or bone marrow derived stem cells may contribute to liver regen-
eration and whether resident stem cells may orchestrate the cell
cycle entry of differentiated cells [9]. Recently, Quesenberry and
Aliotta [19] proposed a dynamic reconsideration of the stem cell
niches suggesting that the lability of stem cell phenotype depends
on complex interactions with differentiated cells based on MV
mediated cell-to-cell transfer of genetic information. Moreover,
these authors suggested that transfer of genetic information from
injured cells may explain stem cell functional and phenotypic
changes without the need of transdifferentiation into tissue cells
[19]. On the other hand, we showed that transfer of genetic infor-
mation from stem cells may re-direct altered functions in target
cells suggesting that stem cells may repair damaged tissues with-
out directly replacing parenchymal cells [21, 23]. Indeed, the
genetic information shuttled by MVs may be exploited to activate
angiogenic and regenerative programs in target cells [21, 23].
Shedding of MVs is no longer considered an artefact [38, 39]
and it has been shown to occur in vivo [24]. It has been suggested
that shedding vesicles could participate in important biological
processes and their significant number at the surface of a Cajal-
like cell of the heart [24] suggests that these structures may trans-
port important information to other cells.
In the present study, we demonstrated that MVs derived from
HLSC may induce in vitro proliferation and apoptosis resistance in
human and rat hepatocytes. HLSC is a pluripotent stem cells pop-
ulation resident in the adult human liver [18]. In vivo HLSC were
shown to contribute to liver regeneration in a model of acute liver
injury in SCID mice [18]. In the present study we found that HLSC
spontaneously released MVs in culture. MVs released from HLSC
had a size similar to that described for MVs released from
endothelial progenitors cells [21] or from bone marrow derived
mesenchymal stem cells [23] and expressed several adhesion
molecules known to be present on the surface of HLSC such as
CD44, CD29 (b1-integrin),  4-integrin. It has been previously
reported that the adhesion molecules expressed by MVs are
instrumental in their internalization into target cells [40]. We found
that  4-integrin blockade prevented MV incorporation into hepato-
cytes whereas blockade of CD44 and CD29 had only minor effects.
Fig. 6 Effect of MVs on liver cell proliferation evaluated as PCNA and Cyclin A1 expression in 70% hepatectomized rats. (A) Quantification of PCNA
 
cells/hpf. Hepatectomized rats injected with vehicle 5 white bars; hepatectomized rats injected with 30  g MVs   black bars; hepatectomized rats
injected with 30  g RNase-treated MVs   shaded bars. Data are expressed as mean   S.D. relative quantity of six different rats per group. Analyses
of variance with Newmann–Keuls multicomparison test was performed; *P   0.05 MV treated versus MV untreated rats; §P   0.05 rats injected with
RNase-treated MVs versus rats injected with MVs. (B) Representative micrographs of PCNA staining performed on sections of livers 24, 48 and 72 hrs
after 70% hepatectomy in rats treated with vehicle (70% Hpt) or treated with 30  g MVs (70% Hpt   MV). Original magnification:  200. (C) Real time
PCR for cyclin A1 (CCNA1) on tissue extract of normal liver (Ctrl; white bars) or liver of hepatectomized rats treated with 30  g MVs (black bars) or of
sham operated rats injected with vehicle alone(grey bar). Data are expressed as mean   S.D. relative quantity of six different rats per group. Analyses
of variance with Newmann–Keuls multicomparison test was performed; *P   0.05 versus MV treated rats versus untreated; §P   0.05 all groups
versus shame operated rats.
Fig. 7 Effect of MVs on apoptosis in 70% hepatectomized rats. (A)
Representative micrographs of TUNEL on liver sections of 70% hepatec-
tomized rats injected with vehicle (70% Hpt) or injected with 30  g MVs
(70% Hpt   MV) and killed at 48 and 72 hrs (6 rats per group). Original
magnification  630. (B) Quantification of TUNEL
  cells/hpf at 72 hrs in
shame operated rats (Ctrl; white bar) or after hepatectomy in rats injected
with vehicle (black bar) and in rats injected with 30  g MVs (grey bar). Data
are expressed as mean   S.D. relative quantity of six different rats per
group. Analyses of variance with Newmann–Keuls multicomparison test
was performed; *P   0.05 hepatectomized rats versus sham operated rats;
§P   0.05 rats injected with MVs versus rats injected with vehicle alone.1616 © 2009 The Authors
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The internalization of MVs in target cells was previously found to
be essential for their biologic activity but not the final mechanism
of action [40]. Indeed, RNase treatment almost completely
  abrogated MV-induced angiogenic and regenerative effects sug-
gesting a critical role of RNA transfer mediated by MVs [21, 23].
In the present study, we found that MV treatment with RNase
abrogated the in vitro proliferation and resistance to apoptosis 
of hepatocytes.
The in vivo administration of MVs derived from HLSC was
found to accelerate liver regeneration in 70% hepatectomized rats.
This was possibly related to an in vivo stimulation of proliferation
of hepatocytes, as indicated by the incorporation of BrdU, the
expression of PCNA and of cyclin A1 by hepatocytes. Moreover,
MV treatment significantly reduced liver apoptosis as seen by
TUNEL. Pre-treatment of MVs with RNase abrogated also the pro-
tective effect of MVs in 70% hepatectomized rats. One can specu-
late that the delivery of exogenous mRNA by MVs to hepatocytes
may stimulate hepatic regeneration. Indeed, MVs derived from
HLSC contained a defined pattern of mRNA associated with sev-
eral cell functions involved in the control of transcription, transla-
tion and proliferation. In vivo evidence for an effective horizontal
transfer of mRNA was obtained by the presence of the human spe-
cific mRNA for AGO2, chosen as reporter gene, and by its de novo
protein expression in the liver of MV-treated hepatectomized rats.
AGO2 is a regulatory protein with a central role in RNA silencing
processes [36]. The results of present study are in line with the
recent evidence that MVs may shuttle biologically active mRNA or
microRNA able to regulate cell function of different target cells
[20–23, 41–43]. Of interest, the pattern of genes present in HLSC-
derived MVs was substantially different from that of endothelial
precursors and mesenchymal stem cells [21, 23] indicating a
specificity for the cell of origin. Moreover, MVs were shown to
contain Staufen 2 suggesting a role of ribonucleoproteins in car-
rying and stabilizing RNAs [37] within MVs.
In conclusion, MV-mediated transfer of mRNA from HLSC to
hepatocytes may represent a mechanism that contribute to liver
regeneration and that could be exploited in regenerative medicine.
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